Biodel Files for IPO

Biodel Inc., a Danbury, Conn.-based drug improvement company focused on endocrine disorders like diabetes and osteoporosis, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol BIOD, with Banc of America Securities serving as lead underwriter. The company raised $21 million in Series B funding last summer, and lists shareholders like Great Point Partners (17.4% pre-IPO stake), OrbiMed Advisors (17.4%) and Vivo Ventures (15%). www.biodelinc.com